
Jens Lagerstedt
Associate professor

Single injections of apoA-I acutely improve in vivo glucose tolerance in insulin-resistant mice.
Author
Summary, in English
Apolipoprotein A-I (apoA-I), the main protein constituent of HDL, has a central role in the reverse cholesterol-transport pathway, which together with the anti-inflammatory properties of apoA-I/HDL provide cardioprotection. Recent findings of direct stimulation of glucose uptake in muscle by apoA-I/HDL suggest that altered apoA-I and HDL functionality may be a contributing factor to the development of diabetes. We have studied the in vivo effects of short treatments with human apoA-I in a high-fat diet fed mouse model. In addition to native apoA-I, we investigated the effects of the cardioprotective Milano variant (Arg173Cys).
Department/s
- EXODIAB: Excellence of Diabetes Research in Sweden
- Medical Protein Science
- Department of Experimental Medical Science
- Genomics, Diabetes and Endocrinology
- Molecular Endocrinology
Publishing year
2014
Language
English
Pages
797-800
Publication/Series
Diabetologia
Volume
57
Issue
4
Links
Document type
Journal article
Publisher
Springer
Topic
- Endocrinology and Diabetes
Status
Published
Research group
- Medical Protein Science
- Genomics, Diabetes and Endocrinology
- Molecular Endocrinology
ISBN/ISSN/Other
- ISSN: 1432-0428